| Primary |
| Drug Use For Unknown Indication |
29.4% |
| Depression |
23.5% |
| Anxiety |
8.8% |
| Post-traumatic Stress Disorder |
8.8% |
| Borderline Personality Disorder |
5.9% |
| Sleep Disorder |
5.9% |
| Constipation |
2.9% |
| Intentional Self-injury |
2.9% |
| Panic Attack |
2.9% |
| Personality Disorder |
2.9% |
| Prophylaxis Of Neural Tube Defect |
2.9% |
| Suicidal Ideation |
2.9% |
|
| Tachycardia |
28.0% |
| Suicide Attempt |
26.9% |
| Vomiting |
11.8% |
| Somnolence |
7.5% |
| Sopor |
6.5% |
| Drug Withdrawal Syndrome |
2.2% |
| Medication Error |
2.2% |
| Premature Rupture Of Membranes |
2.2% |
| Blood Sodium Decreased |
1.1% |
| Condition Aggravated |
1.1% |
| Fall |
1.1% |
| Fatigue |
1.1% |
| Gamma-glutamyltransferase Increased |
1.1% |
| Gastrointestinal Sounds Abnormal |
1.1% |
| Incorrect Dose Administered |
1.1% |
| Intentional Self-injury |
1.1% |
| Neonatal Respiratory Distress Syndrome |
1.1% |
| Neonatal Respiratory Failure |
1.1% |
| Panic Reaction |
1.1% |
| Prothrombin Time Prolonged |
1.1% |
|
| Secondary |
| Drug Use For Unknown Indication |
19.0% |
| Product Used For Unknown Indication |
16.8% |
| Hypertension |
10.4% |
| Supplementation Therapy |
8.4% |
| Psoas Abscess |
5.7% |
| Depression |
5.3% |
| Pain |
5.3% |
| Thrombosis Prophylaxis |
3.7% |
| Ill-defined Disorder |
3.2% |
| Hyperglycaemia |
2.6% |
| Restlessness |
2.5% |
| Anxiety |
2.4% |
| Sepsis |
2.4% |
| Epilepsy |
2.3% |
| Schizophrenia, Paranoid Type |
1.9% |
| Secretion Discharge |
1.8% |
| Polyuria |
1.7% |
| Prophylaxis |
1.7% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.4% |
| Pyrexia |
1.4% |
|
| Suicide Attempt |
14.1% |
| Stevens-johnson Syndrome |
11.7% |
| Tachycardia |
8.6% |
| Toxic Epidermal Necrolysis |
8.6% |
| Sopor |
7.4% |
| Vomiting |
7.4% |
| Self Injurious Behaviour |
5.5% |
| Encephalopathy |
5.1% |
| Urine Colour Abnormal |
5.1% |
| Rhabdomyolysis |
3.1% |
| Spina Bifida |
3.1% |
| Speech Disorder |
2.7% |
| Drug Withdrawal Syndrome |
2.3% |
| Shock |
2.3% |
| Sluggishness |
2.3% |
| Vision Blurred |
2.3% |
| Withdrawal Syndrome |
2.3% |
| Fall |
2.0% |
| Status Epilepticus |
2.0% |
| Toxicity To Various Agents |
2.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
22.7% |
| Drug Use For Unknown Indication |
16.2% |
| Depression |
10.1% |
| Hypertension |
6.8% |
| Pain |
6.8% |
| Tumour Pain |
4.4% |
| Prophylaxis |
3.9% |
| Psychotic Disorder |
3.0% |
| Ill-defined Disorder |
2.7% |
| Epilepsy |
2.5% |
| Nausea |
2.5% |
| Colon Cancer Metastatic |
2.3% |
| Constipation |
2.2% |
| Insomnia |
2.2% |
| Sleep Disorder |
2.2% |
| Schizophrenia, Paranoid Type |
2.0% |
| Thrombosis Prophylaxis |
1.9% |
| Prostate Cancer |
1.9% |
| Schizophrenia |
1.9% |
| Anxiety |
1.7% |
|
| Neutropenia |
8.3% |
| Vomiting |
7.9% |
| Thrombocytopenia |
7.5% |
| Weight Increased |
6.7% |
| Syncope |
6.3% |
| White Blood Cell Count Increased |
6.3% |
| Drug Interaction |
5.1% |
| Polydipsia |
5.1% |
| Suicide Attempt |
4.7% |
| Ventricular Tachycardia |
4.7% |
| Wrong Technique In Drug Usage Process |
4.7% |
| Hyponatraemia |
3.9% |
| Off Label Use |
3.9% |
| Pulmonary Embolism |
3.9% |
| Renal Failure |
3.9% |
| Respiratory Depression |
3.9% |
| Rhabdomyolysis |
3.5% |
| Blood Prolactin Increased |
3.1% |
| Restlessness |
3.1% |
| Somnolence |
3.1% |
|
| Interacting |
| Drug Use For Unknown Indication |
39.6% |
| Product Used For Unknown Indication |
36.8% |
| Depression |
4.7% |
| Musculoskeletal Pain |
3.8% |
| Bipolar I Disorder |
2.8% |
| Mania |
2.8% |
| Panic Attack |
1.9% |
| Schizophrenia |
1.9% |
| Sleep Disorder |
1.9% |
| Chronic Obstructive Pulmonary Disease |
0.9% |
| Gastritis |
0.9% |
| Generalised Anxiety Disorder |
0.9% |
| Respiratory Tract Infection Bacterial |
0.9% |
|
| Vomiting |
22.6% |
| Encephalopathy |
19.4% |
| Syncope |
12.9% |
| Death |
6.5% |
| Restlessness |
6.5% |
| Sedation |
6.5% |
| Somnolence |
6.5% |
| Drug Level Increased |
3.2% |
| Incorrect Route Of Drug Administration |
3.2% |
| Respiratory Depression |
3.2% |
| Respiratory Tract Infection Bacterial |
3.2% |
| Screaming |
3.2% |
| Visual Impairment |
3.2% |
|
